Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell-blocks and hematolymphoid lesions.
Alrajjal A, Choudhury M, Yang J, Gabali A. Alrajjal A, et al. Among authors: yang j. Cytojournal. 2021 Mar 31;18:7. doi: 10.25259/Cytojournal_10_2021. eCollection 2021. Cytojournal. 2021. PMID: 34221096 Free PMC article. Review.
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
Seymour EK, Khan HY, Li Y, Chaker M, Muqbil I, Aboukameel A, Ramchandren R, Houde C, Sterbis G, Yang J, Bhutani D, Pregja S, Reichel K, Huddlestun A, Neveux C, Corona K, Landesman Y, Shah J, Kauffman M, Shacham S, Mohammad RM, Azmi AS, Zonder JA. Seymour EK, et al. Among authors: yang j. Clin Cancer Res. 2021 Jun 15;27(12):3307-3316. doi: 10.1158/1078-0432.CCR-20-4929. Epub 2021 Mar 30. Clin Cancer Res. 2021. PMID: 33785483 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36163774
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Shi W, Assouline S, Sharman J. Burke JM, et al. Among authors: yang j. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331. doi: 10.1016/j.clml.2018.05.022. Epub 2018 Jun 6. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29934062 Free PMC article. Clinical Trial.
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Badar T, et al. Among authors: yang j. Cancer. 2021 Apr 1;127(7):1039-1048. doi: 10.1002/cncr.33340. Epub 2020 Dec 1. Cancer. 2021. PMID: 33259056 Free article.
85,123 results
You have reached the last available page of results. Please see the User Guide for more information.